Literature DB >> 10389976

Sequence analysis and transcript expression of the MEN1 gene in sporadic pituitary tumours.

W E Farrell1, D J Simpson, J Bicknell, J L Magnay, E Kyrodimou, R V Thakker, R N Clayton.   

Abstract

The majority of pituitary tumours are monoclonal in origin and arise sporadically or occasionally as part of multiple endocrine neoplasia type 1 (MEN1). Whilst a multi-step aetiology involving both oncogenes and tumour suppressor genes has been proposed for their development, the target(s) of these changes are less clearly defined. Both familial and sporadic pituitary tumours have been shown to harbour allelic deletion on 11q13, which is the location of the recently cloned MEN1 gene. We investigated 23 sporadic pituitary tumours previously shown to harbour allelic deletion on 11q13 with the marker PYGM centromeric and within 50 kb of the MEN1 locus. In addition, the use of intragenic polymorphisms in exon 9 and at D11S4946, and of telomeric loci at D11S4940 and D11S4936, revealed that five of 20 tumours had loss of heterozygosity (LOH) telomeric to the menin gene. However, the overall pattern of loss in informative cases was indicative of non-contiguous deletion that brackets the menin gene. Sequence analysis of all MEN1 coding exons and flanking intronic sequence, in tumours and matched patient leucocyte DNA, did not reveal mutation(s) in any of the 23 tumours studied. A benign polymorphism in exon 9 was encountered at the expected frequency, and in seven patients heterozygous for the polymorphism the tumour showed retention of both copies of the menin gene. Reverse transcription polymerase chain reaction analysis of ten evaluable tumours and four normal pituitaries revealed the presence of the menin transcript. Whilst these findings suggest that gene silencing is unlikely to be mechanistic in sporadic pituitary tumorigenesis, they do not exclude changes in the level or stability of the transcript or translation to mature protein. Our study would support and extend very recent reports of a limited role for mutations in the MEN1 gene in sporadic pituitary tumours. Alternatively, these findings may point to an, as yet, unidentified tumour suppressor gene in this region.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10389976      PMCID: PMC2363023          DOI: 10.1038/sj.bjc.6690319

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  31 in total

1.  A new constitutively activating mutation of the Gs protein alpha subunit-gsp oncogene is found in human pituitary tumours.

Authors:  E Clementi; N Malgaretti; J Meldolesi; R Taramelli
Journal:  Oncogene       Date:  1990-07       Impact factor: 9.867

2.  GTPase inhibiting mutations activate the alpha chain of Gs and stimulate adenylyl cyclase in human pituitary tumours.

Authors:  C A Landis; S B Masters; A Spada; A M Pace; H R Bourne; L Vallar
Journal:  Nature       Date:  1989-08-31       Impact factor: 49.962

3.  Characterization of mutations in patients with multiple endocrine neoplasia type 1.

Authors:  J H Bassett; S A Forbes; A A Pannett; S E Lloyd; P T Christie; C Wooding; B Harding; G M Besser; C R Edwards; J P Monson; J Sampson; J A Wass; M H Wheeler; R V Thakker
Journal:  Am J Hum Genet       Date:  1998-02       Impact factor: 11.025

4.  Two G protein oncogenes in human endocrine tumors.

Authors:  J Lyons; C A Landis; G Harsh; L Vallar; K Grünewald; H Feichtinger; Q Y Duh; O H Clark; E Kawasaki; H R Bourne
Journal:  Science       Date:  1990-08-10       Impact factor: 47.728

5.  Hypermethylation of the p16/CDKN2A/MTSI gene and loss of protein expression is associated with nonfunctional pituitary adenomas but not somatotrophinomas.

Authors:  D J Simpson; J E Bicknell; A M McNicol; R N Clayton; W E Farrell
Journal:  Genes Chromosomes Cancer       Date:  1999-04       Impact factor: 5.006

Review 6.  The molecular genetics of the multiple endocrine neoplasia syndromes.

Authors:  R V Thakker
Journal:  Clin Endocrinol (Oxf)       Date:  1993-01       Impact factor: 3.478

7.  Allelic loss from chromosome 11 in parathyroid tumors.

Authors:  E Friedman; L De Marco; P V Gejman; J A Norton; A E Bale; G D Aurbach; A M Spiegel; S J Marx
Journal:  Cancer Res       Date:  1992-12-15       Impact factor: 12.701

8.  Clinically nonfunctioning pituitary tumors are monoclonal in origin.

Authors:  J M Alexander; B M Biller; H Bikkal; N T Zervas; A Arnold; A Klibanski
Journal:  J Clin Invest       Date:  1990-07       Impact factor: 14.808

9.  Clonal origin of pituitary adenomas.

Authors:  V Herman; J Fagin; R Gonsky; K Kovacs; S Melmed
Journal:  J Clin Endocrinol Metab       Date:  1990-12       Impact factor: 5.958

10.  Localization of the MEN1 gene to a small region within chromosome 11q13 by deletion mapping in tumors.

Authors:  C Byström; C Larsson; C Blomberg; K Sandelin; U Falkmer; B Skogseid; K Oberg; S Werner; M Nordenskjöld
Journal:  Proc Natl Acad Sci U S A       Date:  1990-03       Impact factor: 11.205

View more
  14 in total

1.  Pituitary adenomas in man and mouse: oncogenic potential of a truncated fibroblast growth factor receptor 4.

Authors:  Malcolm J Low
Journal:  J Clin Invest       Date:  2002-01       Impact factor: 14.808

2.  Unique gene expression profile associated with an early-onset multiple endocrine neoplasia (MEN1)-associated pituitary adenoma.

Authors:  William E Farrell; Monalisa F Azevedo; Dalia L Batista; Alastair Smith; Isabelle Bourdeau; Anelia Horvath; Margaret Boguszewski; Martha Quezado; Constantine A Stratakis
Journal:  J Clin Endocrinol Metab       Date:  2011-09-14       Impact factor: 5.958

3.  Screening for MEN1 tumor suppressor gene mutations in sporadic pituitary tumors.

Authors:  C O Evans; M R Brown; J S Parks; N M Oyesiku
Journal:  J Endocrinol Invest       Date:  2000-05       Impact factor: 4.256

Review 4.  Molecular basis of pituitary oncogenesis.

Authors:  M Tada; H Kobayashi; T Moriuchi
Journal:  J Neurooncol       Date:  1999       Impact factor: 4.130

Review 5.  Genetic mutations in sporadic pituitary adenomas--what to screen for?

Authors:  Anne-Lise Lecoq; Peter Kamenický; Anne Guiochon-Mantel; Philippe Chanson
Journal:  Nat Rev Endocrinol       Date:  2014-10-28       Impact factor: 43.330

6.  Tumor deletion mapping of chromosomal region 13q14 in 43 growth hormone secreting pituitary adenomas.

Authors:  Ines Donangelo; Paula Bruna Araújo; Daniela Antenuzi; Mariana Farage; Jorge Marcondes; Paulo Niemeyer Filho; Mônica R Gadelha
Journal:  Endocrine       Date:  2005-11       Impact factor: 3.633

Review 7.  The molecular biology of pituitary tumors: a personal perspective.

Authors:  Ashley B Grossman
Journal:  Pituitary       Date:  2009       Impact factor: 4.107

Review 8.  Familial isolated pituitary adenomas (FIPA) and the pituitary adenoma predisposition due to mutations in the aryl hydrocarbon receptor interacting protein (AIP) gene.

Authors:  Albert Beckers; Lauri A Aaltonen; Adrian F Daly; Auli Karhu
Journal:  Endocr Rev       Date:  2013-01-31       Impact factor: 19.871

Review 9.  Genetic and epigenetic mutations of tumor suppressive genes in sporadic pituitary adenoma.

Authors:  Yunli Zhou; Xun Zhang; Anne Klibanski
Journal:  Mol Cell Endocrinol       Date:  2013-09-11       Impact factor: 4.102

10.  Molecular pathogenesis of human prolactinomas identified by gene expression profiling, RT-qPCR, and proteomic analyses.

Authors:  Chheng-Orn Evans; Carlos S Moreno; Xianquan Zhan; Michael T McCabe; Paula M Vertino; Dominic M Desiderio; Nelson M Oyesiku
Journal:  Pituitary       Date:  2008       Impact factor: 4.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.